Postradiation Problems Cause Long-Term Pain

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 11
Volume 8
Issue 11

VIENNA, Austria-Most long-term breast cancer survivors who have had adjuvant radiotherapy are likely to have significant pain or functional impairment even 10 to 16 years after treatment, but fewer than one third receive pain medication, Ulf E. Kongsgaard, MD, of the Norwegian Radium Hospital, Oslo, said at the 9th World Congress on Pain.

VIENNA, Austria—Most long-term breast cancer survivors who have had adjuvant radiotherapy are likely to have significant pain or functional impairment even 10 to 16 years after treatment, but fewer than one third receive pain medication, Ulf E. Kongsgaard, MD, of the Norwegian Radium Hospital, Oslo, said at the 9th World Congress on Pain.

From a series of 2,113 women who had been treated with adjuvant radiotherapy to the breast wall and/or regional lymph nodes, the researchers evaluated 354 of the 450 patients who survived until 1996. Median observation was 10 years for women who had been treated with 2.5 Gy × 20 and 16 years for women who had been treated with 4.3 Gy × 10.

“Arm edema, fractures of the ribs, and impaired shoulder function were the three most objective factors predicting late radiation side effects,” Dr. Kongs-gaard reported. “Pain interference in the patient’s life, evaluated by the Brief Pain Inventory (BPI), was characteristic in most patients.”

Patients who had received the 4.3 Gy dose had more severe late effects than those treated with the 2.5 Gy dose. Median BPI pain scores were 19 of a possible 40 after 4.3 Gy and 15 of a possible 40 after 2.5 Gy. Median BPI reduced function scores were 34 of a possible 70 and 26 of a possible 70, respectively.

“Despite a high sum on the BPI pain score, only 136 patients (37%) were on pain medication,” Dr. Kongsgaard said. These included 61 patients (15%) on acetaminophen, 67 (14%) on acetamino-phen plus codeine, and 25 (6%) on aspirin or NSAIDs. Four patients were taking antidepressants, and none were on anti-convulsants. Only 9 patients (2%) were taking strong opioids.

The investigators concluded, “Late sequelae after breast irradiation are associated with physical and psychological distress compromising quality of life. These problems are possibly underestimated.”

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content